Results 71 to 80 of about 385 (131)

Myosin Modulators Mavacamten and Aficamten Inhibit Cardiac Contractility Through Different Mechanisms

Journal of Molecular and Cellular Cardiology Plus
Saffie Mohran, Kristina Kooiker, Galina Flint, Max Mahoney-Schaefer, Weikang Ma, Timothy McMillen, Thomas Irving, Michael Regnier, Farid Moussavi-Harami   +8 more
doaj   +1 more source

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. [PDF]

Circulation
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD.   +23 more
europepmc   +1 more source

Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition. [PDF]

Eur Heart J Open
Govind A.
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Cardiovascular pharmacotherapy in 2025. [PDF]

Eur Heart J Cardiovasc Pharmacother
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan GA, Drexel H, Ferdinandy P, Grove EL, Klingenberg R, Morais J, Parker W, Rocca B, Sulzgruber P, Semb AG, Sossalla S, Kaski JC, Dobrev D.   +17 more
europepmc   +1 more source

Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. [PDF]

Clin Pharmacokinet
Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P.   +8 more
europepmc   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study

Journal of Cardiovascular Magnetic Resonance
Ahmad Masri, MD, Rhanderson Cardoso, MD, Theodore Abraham, MD, Lubna Choudhury, MD, Florian Rader, MD, Sara Saberi, MD, Albree Tower-Rader, MD, Andrew Wang, MD, Stephen Heitner, MD, Stuart Kupfer, MD, Fady Malik, MD, PhD, Chiara Melloni, MD, Jenny Wei, PhD, Amy Wohltman, Raymond Kwong, MD   +14 more
doaj   +1 more source

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +1 more source

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. [PDF]

Eur Heart J
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I.   +17 more
europepmc   +1 more source